Clinical bottom line
Emerging anti-CD123 monoclonal antibody therapies represent a novel immunotherapeutic approach primarily targeting hematologic malignancies such as acute myeloid leukemia (AML). These agents may alter host immune defenses and predispose patients to infections, but current clinical evidence on infectious risks and management remains limited and largely extrapolated from related biologic therapies. Clinicians should maintain heightened vigilance for serious infections, including opportunistic and mycobacterial infections, in patients receiving anti-CD123 antibodies, applying principles of infection risk assessment and prophylaxis used for other immunomodulatory biologics. Prospective data are needed to define infection incidence, spectrum, and optimal management strategies in this population.
What the evidence shows
Anti-CD123 monoclonal antibodies, such as KHK2823 and CSL360, target the interleukin-3 receptor alpha chain (CD123), which is overexpressed on leukemic blasts and certain immune cells (National Cancer Institute et al., 2020). By depleting CD123-expressing cells, these therapies may impair innate and adaptive immunity, potentially increasing susceptibility to infections.
Direct clinical data on infection risks with anti-CD123 agents are sparse. However, experience with other novel biologics that modulate immune function provides a framework for understanding potential infectious complications. For example, Winthrop et al. (2008) described increased risks of mycobacterial and other serious infections in patients receiving anti–tumor necrosis factor (TNF) and other newly approved biologic therapies, highlighting the need for careful infection surveillance and prophylaxis in immunomodulated patients.
Similarly, anti-CD38 monoclonal antibodies, which also target immune cell populations, have been associated with increased infection risk, necessitating practical management strategies including antimicrobial prophylaxis and monitoring (Moreau et al., 2015). These insights may be cautiously extrapolated to anti-CD123 therapies given overlapping immunosuppressive mechanisms.
Bispecific antibodies targeting CD123 in combination with CD3, such as XmAb1404 and SAR440234, are under investigation (National Cancer Institute et al., 2020). These agents engage T cells to target leukemic cells but may also induce immune dysregulation, further complicating infection risk profiles.
Caveats and uncertainty
The infectious risk profile specific to anti-CD123 monoclonal antibodies remains incompletely characterized. Available data derive primarily from early-phase trials and mechanistic studies rather than large-scale clinical cohorts. The heterogeneity of patient populations, underlying malignancies, and concomitant therapies complicates attribution of infections solely to anti-CD123 agents.
Extrapolation from other biologics, while informative, may not fully capture unique immune effects of anti-CD123 therapies. For example, differential depletion of dendritic cells or myeloid progenitors could alter host defense in ways not seen with anti-TNF or anti-CD38 antibodies.
Furthermore, the spectrum of infections—including bacterial, viral, fungal, and mycobacterial—has not been systematically defined. The role of latent infection screening, vaccination, and antimicrobial prophylaxis protocols specific to anti-CD123 therapy is yet to be established.
How this may change practice
Clinicians managing patients receiving anti-CD123 monoclonal antibodies should adopt a cautious, proactive approach to infection risk mitigation. This includes:
- Baseline assessment for latent infections, such as tuberculosis, informed by experience with other biologics (Winthrop et al., 2008).
- Consideration of antimicrobial prophylaxis tailored to patient risk factors and local epidemiology.
- Vigilant monitoring for signs of infection during and after therapy, with low thresholds for diagnostic evaluation.
- Coordination with infectious disease specialists for management of complex or opportunistic infections.
- Patient education regarding infection symptoms and prompt reporting.
As clinical experience and trial data accumulate, infection prevention and management guidelines specific to anti-CD123 therapies will need to be developed. Until then, applying principles from related immunomodulatory therapies offers a prudent interim strategy.